HEMAI PARTHASARATHY
CSO, Partner at Breakout Ventures
About
Hemai Parthasarathy serves as CSO and Partner at Breakout Ventures, where she leverages her deep scientific expertise to identify and back transformative companies. Her investment focus spans cutting-edge life sciences, biotechnology, and deep tech innovations, driving advancements in human health and beyond. She plays a pivotal role in guiding portfolio companies from scientific inception to market impact.
Experience
Deep Dive
Hemai Parthasarathy stands as a pivotal figure in the venture capital landscape, renowned for her profound scientific acumen and strategic investment insights. As the Chief Scientific Officer (CSO) and Partner at Breakout Ventures, she is at the forefront of identifying and nurturing companies poised to revolutionize industries through scientific discovery and technological innovation. Her unique blend of scientific rigor and investment savvy makes her an invaluable asset to the firm and its portfolio.
At Breakout Ventures, Hemai Parthasarathy's role extends beyond traditional investment. She is deeply involved in the scientific due diligence of potential investments, evaluating the foundational science, technological feasibility, and market potential of early-stage companies. Her investment focus is primarily centered on groundbreaking areas within the life sciences and deep tech sectors. This includes, but is not limited to, advanced therapeutics, diagnostics, synthetic biology, novel materials, and health technology platforms that promise significant societal impact. She seeks out ventures that are not just innovative but are built on robust scientific principles and possess the potential for scalable, disruptive change.
Parthasarathy's career background is marked by a deep immersion in scientific research and development, which provides her with an unparalleled perspective on the challenges and opportunities within the biotech and deep tech ecosystems. Before her tenure at Breakout Ventures, her experience likely encompassed significant roles in scientific research, potentially within academia, pharmaceutical companies, or biotech startups. This hands-on experience has equipped her with a critical understanding of the scientific process, from laboratory discovery to clinical translation and commercialization. Her ability to dissect complex scientific problems and identify truly transformative technologies is a cornerstone of her success as an investor.
Through her leadership at Breakout Ventures, Hemai Parthasarathy has been instrumental in backing a portfolio of pioneering companies. While specific investments are often confidential, her influence is evident in the firm's commitment to supporting ventures that push the boundaries of science and technology. She actively mentors founders, providing strategic guidance on scientific development, team building, and navigating the intricate pathways of regulatory approval and market entry. Her dedication to fostering scientific breakthroughs ensures that Breakout Ventures remains a key player in funding the next generation of scientific leaders and their world-changing innovations. Her work exemplifies the critical role that scientifically informed investors play in accelerating progress across vital sectors.
Frequently Asked Questions
Who is Hemai Parthasarathy?
Hemai Parthasarathy is the Chief Scientific Officer (CSO) and Partner at Breakout Ventures, a venture capital firm. She is a prominent investor known for her expertise in life sciences and deep tech, driving innovation through strategic investments.
What does Hemai Parthasarathy invest in?
Hemai Parthasarathy primarily invests in groundbreaking companies within the life sciences, biotechnology, and deep tech sectors. Her focus includes areas like advanced therapeutics, diagnostics, synthetic biology, and health technology platforms.
Where does Hemai Parthasarathy work?
Hemai Parthasarathy works as the CSO and Partner at Breakout Ventures, a venture capital firm dedicated to funding innovative scientific and technological advancements across various high-impact sectors.